Core Viewpoint - The announcement highlights that the company's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received the drug registration certificate for Nimodipine injection from the National Medical Products Administration of China, indicating a significant regulatory milestone for the company in the pharmaceutical sector [1]. Group 1: Company Developments - The company, Guangdong Tianen Pharmaceutical Co., Ltd., has made progress in its product pipeline by obtaining the registration certificate for Nimodipine injection, which is a critical step for market entry [1]. - The Nimodipine injection is a calcium antagonist that selectively acts on cerebral vascular smooth muscle, promoting relaxation of cerebral arteries and improving blood circulation during recovery from acute cerebrovascular diseases [1]. Group 2: Product Information - Nimodipine injection was developed by BayerVital GmbH and was first approved for market in Germany in 1985 under the brand name Nimotop, with a specification of 50ml:10mg [1]. - The original Nimodipine injection was imported into China in 2004, indicating its established presence in the market prior to the company's recent approval [1].
泰恩康(301263.SZ)全资子公司收到尼莫地平注射液药品注册证书